New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
12:50 EDTSVU, PHH, MET, GAME, NKTRHigh option volume stocks: PHH NKTR MET SVU GAME
News For PHH;NKTR;MET;SVU;GAME From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
10:11 EDTSVUHigh option volume stocks
High option volume stocks: AERI UEC NUAN DSW CHU SVU PII ACTG GIMO JNPR
April 17, 2015
13:12 EDTSVUSupervalu volatility elevated into Q1 and outlook
Subscribe for More Information
April 16, 2015
09:03 EDTNKTRBaxter submits application to Japan's MHLW for approval of BAX 855
Baxter International (BAX) announced that the company has submitted a new drug application to Japanís Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII treatment based on ADVATE for patients over 12 years of age with hemophilia A. The submission follows the filing to the United States Food and Drug Administration in late 2014 and is based on positive results from a prospective, global, Phase 3 study of 137 previously treated patients. The results, presented during the European Association for Haemophilia and Allied Disorders meeting in February 2015, demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding episodes and routine prophylaxis for patients who were 12 years or older. Baxter continues to advance a continuation study for patients who completed the pivotal trial and a Phase 3 study among previously treated patients under the age of 12 with severe hemophilia A. Once the pediatric study has been completed, the company expects to file for marketing authorization with the European Medicines Agency in 2016 and intends to seek post-approval label expansion in the U.S. for previously-untreated pediatric patients. BAX 855 is based on ADVATE, a full-length FVIII molecule with more than 12 years of real-world experience. Through a collaboration with Nektar Therapeutics (NKTR), BAX 855 leverages proprietary pegylation technology designed to extend the duration of activity of the protein in the body. This proprietary technology has been used for over 10 years in a number of approved medicines that treat chronic or serious conditions.
April 15, 2015
10:36 EDTMETBofA/Merrill U.S. credit analysts hold an analyst/industry conference call
Subscribe for More Information
April 14, 2015
10:42 EDTMETWheeler retirement adds uncertainty to MetLife CEO succession, says Wells Fargo
Wells Fargo said the retirement of Metlife's President of the Americas Bill Wheeler was unexpected and adds uncertainty around the issue of CEO succession, since Wheeler was widely viewed as a possible successor to CEO Steve Kandarian. Wheeler's exit leaves the company with no clear front runner to next take up the CEO post, said the firm, which has an Outperform rating on Metlife shares.
08:36 EDTMETMetLife announces retirement of president of Americas Bill Wheeler
Subscribe for More Information
April 13, 2015
14:18 EDTSVUTarget names Anne Dament as SVP, Merchandising
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use